MCAS

KPV acts intracellularly to inhibit NF-kB activation and downstream pro-inflammatory cytokine transcription, calming the immune signaling that amplifies mast-cell reactivity. Crucially for MCAS, KPV is a small, non-cationic peptide and lacks the basic-secretagogue chemistry that activates MRGPRX2 (the receptor exploited by cationic peptides and drugs to cause IgE-independent degranulation) — so the rationale is 'quiet inflammation without pulling the degranulation trigger.'

Preclinical only, and thin. According to PubMed, the best direct KPV data is an anti-inflammatory effect in a DSS-colitis mouse model, with in-vitro confirmation of reduced LPS-driven inflammation in intestinal epithelial (Caco2-BBE) cells — and in that study KPV was delivered by targeted nanoparticles rather than as free peptide (Laroui et al., Gastroenterology 2009). There is no human trial in MCAS and no study directly testing KPV on human mast-cell degranulation or MRGPRX2 — the 'does not degranulate' claim is a reasonable structural inference, not a measured result. Grade of preclinical is correct; the mast-cell-specific claim should be read strictly as mechanistic hypothesis.

Anecdotal community signal only, not evidence: in MCAS and long-COVID forums KPV is discussed as a 'gentle' anti-inflammatory that some patients say they tolerate better than other peptides, often taken orally or intranasally to avoid injection-site reactions. Reports are mixed and uncontrolled — a subset describe reduced flushing/GI symptoms, others notice nothing; none of this constitutes evidence of efficacy or of mast-cell safety.

Context, not a protocol: community and compounding-pharmacy ranges are typically ~250-500 mcg per dose, oral/intranasal or subcutaneous, once or twice daily, often run in short cycles. No validated MCAS dosing exists and the bioavailability of oral KPV is poorly characterized.

MCAS-specific flag: even though KPV itself is not expected to be a mast-cell secretagogue, MCAS patients frequently react to excipients, preservatives, and injection trauma rather than the active peptide — so vehicle/formulation matters more than usual. As an alpha-MSH fragment it sits in melanocortin signaling; theoretical overlap with pigmentation/appetite pathways is unquantified at these doses. No known mast-cell-stabilizer interactions, but data are absent, so introduce cautiously and single-agent.

• Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. ↗